MedTech Executive Amy Dodrill Appointed to PROCEPT BioRobotics Board of Directors

REDWOOD CITY, Calif., June 15, 2021 /PRNewswire/ -- PROCEPT® BioRobotics Corporation ("PROCEPT" or "PROCEPT BioRobotics"), a surgical robotics company developing intelligent solutions to transform the field of urology, today announced the appointment of Amy Dodrill to its board of directors. Ms. Dodrill has served healthcare and technology companies for more than 20 years and is currently the President of Global Surgical Solutions at Hill-Rom Holdings, Inc. ("Hillrom"). During her eight-year tenure at Hillrom she has been responsible for achieving enhanced operational effectiveness, market expansion and market share growth.

"We are pleased to welcome Ms. Dodrill to PROCEPT as part of our commitment to maintaining a well-balanced Board and upholding strong corporate governance practices. Ms. Dodrill brings a successful commercial background and public company medical device industry experience that will complement our current directors' considerable skills and expertise," said Reza Zadno, president and chief executive officer of PROCEPT BioRobotics.

Prior roles at Hillrom include Vice President and General Manager, US Surgical Division, Vice President and General Manager of Trumpf Medical Surgical Solutions NA and Area Vice President & General Manager. Earlier in her career, she served as a Vice President, Commercial Operations at DynaVox, and prior to that was a Regional Vice President at GE Healthcare. Ms. Dodrill earned a degree in biomedical engineering from Johns Hopkins University.

"I am delighted to join the Board of Directors at PROCEPT BioRobotics. The company's rapid growth is very exciting and I am looking forward to seeing PROCEPT address the tradeoffs and complications that exist with the current BPH treatment options available to patients and surgeons," said Ms. Dodrill.

About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company enabling better patient care by developing transformative solutions in urology. With an initial focus on BPH, the AquaBeam Robotic System delivering Aquablation therapy is the first FDA-cleared, surgical robot with automated tissue resection for the treatment of lower urinary tract symptoms due to BPH. Aquablation therapy combines real-time, multi-dimensional imaging, automated robotics and heat-free waterjet ablation for targeted, controlled, and immediate removal of prostate tissue. Aquablation therapy offers predictable and reproducible outcomes, independent of prostate anatomy, prostate size or surgeon experience. For more information visit https://www.procept-biorobotics.com.

Safety Information: https://www.procept-biorobotics.com/safety-info/

Media Contact:
JPA Health
[email protected] 

SOURCE PROCEPT BioRobotics

Related Links

http://www.procept-biorobotics.com